Telomir Pharmaceuticals Files Q1 2025 10-Q
Ticker: TELO · Form: 10-Q · Filed: May 14, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Telomir Pharma filed its Q1 2025 10-Q. Check financials.
AI Summary
Telomir Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, based in Miami, Florida, operates in the pharmaceutical preparations sector. This filing provides an update on its financial status and business operations for the first quarter of 2025.
Why It Matters
This filing provides investors with the latest financial and operational details for Telomir Pharmaceuticals, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Telomir is subject to regulatory risks, clinical trial outcomes, and market competition, which can significantly impact its financial performance.
Key Numbers
- Q1 2025 — Reporting Period (The first quarter of 2025, for which financial information is reported.)
- 20250514 — Filing Date (The date the 10-Q report was filed with the SEC.)
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Filer of the 10-Q report.
- 20250331 (date) — End of the reporting period for the 10-Q.
- Miami, Florida (location) — Location of Telomir Pharmaceuticals' business and mailing address.
- 2834 (industry_code) — Standard Industrial Classification code for Pharmaceutical Preparations.
FAQ
What is the primary business of Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
Where is Telomir Pharmaceuticals, Inc. located?
Telomir Pharmaceuticals, Inc. is located in Miami, Florida.
When was this 10-Q report filed?
This 10-Q report was filed on May 14, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).